Polydex Pharmaceuticals Limited

OTCPK:POLX.F Stock Report

Market Cap: US$6.8m

Polydex Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Polydex Pharmaceuticals's earnings have been declining at an average annual rate of -74.3%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been declining at an average rate of 3.8% per year.

Key information

-74.3%

Earnings growth rate

-74.3%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate-3.8%
Return on equity-17.4%
Net Margin-17.8%
Last Earnings Update30 Apr 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Polydex Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:POLX.F Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Apr 235-110
31 Jan 234-110
31 Oct 224-110
31 Jul 224-110
30 Apr 225010
31 Jan 224-110
31 Oct 215010
31 Jul 215010
30 Apr 215010
31 Jan 215010
31 Oct 205010
31 Jul 205010
30 Apr 205010
31 Jan 205010
31 Oct 195010
31 Jul 195010
30 Apr 195010
31 Jan 195010
31 Oct 185010
31 Jul 185010
30 Apr 185010
31 Jan 185010
31 Oct 176010
31 Jul 176010
30 Apr 176110
31 Jan 177110
31 Oct 166110
31 Jul 166110
30 Apr 166110
31 Jan 166110
31 Oct 156110
31 Jul 156110
30 Apr 156110
31 Jan 155110
31 Oct 145010
31 Jul 145010
30 Apr 146010
31 Jan 146110
31 Oct 136010
31 Jul 136010
30 Apr 135010
31 Jan 135010
31 Oct 125010

Quality Earnings: POLX.F is currently unprofitable.

Growing Profit Margin: POLX.F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: POLX.F is unprofitable, and losses have increased over the past 5 years at a rate of 74.3% per year.

Accelerating Growth: Unable to compare POLX.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: POLX.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-17.3%).


Return on Equity

High ROE: POLX.F has a negative Return on Equity (-17.38%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.